The drug, which treats brain cancers including glioblastoma, does not have a generic alternative and can cost as much as $1,000 per capsule, the article said.
In a statement to the Journal, NextSource said it is exploring a new contract with the program and plans to participate again in the future, though it did not specify why the drug’s coverage benefits ended Jan. 1.
NextSource also told the publication that Medicare patients meeting certain income criteria have been eligible to receive the drug at no cost since January.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
